Please enable JS



Collaborations and business development are integral to our growth strategy and have played a key role in our complex generics and biosimilars business.

Complex Generics

Momenta has two major complex generic collaborations with Sandoz, a division of Novartis.

  • In 2003, Momenta entered into a collaboration and license agreement with Sandoz for the development and commercialization of enoxaparin sodium injection in the United States. The resulting product, marketed by Sandoz, was the first generic version of LOVENOX® (enoxaparin sodium injection) to be approved by the FDA.
  • In 2006, Momenta and Sandoz entered into a collaboration and license agreement for the worldwide development and commercialization of a generic form of daily COPAXONE® 20 mg/mL (glatiramer acetate injection). The resulting product, marketed by Sandoz, Glatopa® is the first fully substitutable once daily generic equivalent of daily COPAXONE® 20 mg/mL to be approved by the FDA.  In January 2018, Sandoz received FDA approval of their Abbreviated New Drug Application for a three times weekly COPAXONE® 40mg/mL (glatiramer acetate injection).


In January 2016, Momenta entered into a broad global collaboration with Mylan for the development, manufacture and commercialization of six of Momenta’s biosimilar candidates. In October 2018, as part of a corporate restructuring, Momenta initiated discussions with Mylan to exit its participation in the development of its other biosimilar programs including M834, a proposed biosimilar to ORENCIA®. Momenta intends to focus solely on the continued development of M710.

Novel Drugs for Autoimmune Indications

In January 2017, Momenta entered into an exclusive research collaboration and worldwide license agreement with CSL to develop and commercialize Fc multimer proteins, including M230, a selective immunomodulator of Fc receptors. In addition to advancing M230, CSL and Momenta will collaborate to develop additional Fc multimer proteins that may originate from Momenta's or CSL's research.

What type of collaborations are we looking for?

Momenta is currently pursuing development or commercial stage collaborations in the following areas:

  • Biosimilars (including potentially interchangeable biologics)
  • Complex Generics
  • Novel drugs for autoimmune diseases or other specialty areas

If you are interested in pursuing a collaboration opportunity with Momenta Pharmaceuticals, or have a technology you wish to introduce to our team, we welcome you to contact us at


LOVENOX® is a registered trademark of Sanofi-Aventis. COPAXONE® is a registered trademark of Teva Pharmaceutical Industries Ltd.  Glatopa® is a trademark of Novartis AG.

Last Updated 4/14/2017